Skip to content
Clinical Trials – home
AustriaBack to Austria

Clinical trials in Schwaz – page 8

373 clinical trials in Schwaz, Austria. Every trial is listed in the EU Clinical Trials Register and updated daily.

Schwaz at a glance
373
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

373 trials in Schwaz

Open in trial search

Study of Sacituzumab Tirumotecan and Pembrolizumab for Patients with Advanced or Recurrent Endometrial Cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Merck Sharp & Dohme LLC

Study of Seladelpar Treatment in Patients with Primary Biliary Cholangitis and Compensated Cirrhosis

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Seladelpar
  • Sponsor:Gilead Sciences Inc.

Study comparing NVL-655 to alectinib in untreated patients with ALK-positive advanced non-small cell lung cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:NVL-655
  • Sponsor:Nuvalent Inc.

Study of Trastuzumab Deruxtecan and Drug Combination for Patients with Advanced or Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Daiichi Sankyo Inc.

Study on Ivosidenib, Azacitidine, and Venetoclax for Adults with Newly Diagnosed IDH1-Mutated Acute Myeloid Leukemia Ineligible for Intensive Chemotherapy

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Study on the Safety and Effects of NSC001 and Trospium Chloride for Patients with Mild to Moderate Alzheimer's Disease

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:NGX-267
  • Sponsor:Nsc Therapeutics GmbH

Study of Sacituzumab Tirumotecan and Bevacizumab for Patients with Recurrent Ovarian Cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Merck Sharp & Dohme LLC

Study on Venetoclax, Obinutuzumab, and Pirtobrutinib for Patients with Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Obinutuzumab
  • Sponsor:University Of Cologne

Study on the Effects of Alpha-1 Antitrypsin and Prednisolone in Patients with Severe Alcohol-Related Hepatitis

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:ALPHA-1-ANTITRYPSIN
  • Sponsor:Medizinische Universitaet Innsbruck

Study on ICEF15 for Treating Fecal Incontinence in Patients with Anal Sphincter Dysfunction

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:ICEF15
  • Sponsor:Innovacell GmbH

Study on Axatilimab and Corticosteroids for Initial Treatment of Chronic Graft-Versus-Host Disease in Patients

Registered drug
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Axatilimab
  • Sponsor:Incyte Corp.

Crohn's disease

Recruiting

Study on the Effectiveness and Safety of Vedolizumab and Upadacitinib in Adults with Moderate to Severe Crohn's Disease

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Upadacitinib
  • Sponsor:Takeda Development Center Americas Inc.

Other cities in Austria

The busiest research cities in the country

All 48 cities in Austria

Clinical research in Schwaz

What the registry says about research in the country

01 Advanced Breast Cancer Research

Clinical trials focusing on HER2-positive breast cancer treatment, evaluating novel combination therapies with tucatinib, pertuzumab, and trastuzumab for patients with advanced or metastatic disease.

  • Treatment Evaluation
  • Disease Progression Assessment
  • Combination Therapy

Research aims to measure progression-free survival using established evaluation criteria.

02 Targeted Therapy Studies

Investigation of elacestrant plus everolimus in treating patients with specific breast cancer subtypes, particularly focusing on those with estrogen receptor-positive and HER2-negative disease.

  • ESR1-Mutation Research
  • Endocrine Therapy
  • CDK4/6 Inhibitor Studies

Double-blind studies examining effectiveness in patients who have progressed after previous treatments.

03 Precision Medicine Applications

Advanced research incorporating biomarker-driven approaches in breast cancer treatment, with specific focus on hormone receptor status and genetic mutations.

  • Biomarker Analysis
  • Treatment Resistance
  • Personalized Medicine

Studies utilize imaging review committees to ensure accurate assessment of treatment outcomes.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.